Entry Point Capital, LLC Xenon Pharmaceuticals Inc. Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 4,541 shares of XENE stock, worth $178,234. This represents 0.18% of its overall portfolio holdings.
Number of Shares
4,541Holding current value
$178,234% of portfolio
0.18%Shares
1 transactions
Others Institutions Holding XENE
# of Institutions
228Shares Held
69MCall Options Held
307KPut Options Held
68.9K-
Avoro Capital Advisors LLC New York, NY5.67MShares$222 Million2.94% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.32MShares$170 Million2.04% of portfolio
-
Wellington Management Group LLP Boston, MA3.92MShares$154 Million0.03% of portfolio
-
Capital World Investors Los Angeles, CA2.68MShares$105 Million0.02% of portfolio
-
Polar Capital Holdings PLC London, X02.61MShares$103 Million0.7% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.44B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...